Latest Breaking News On - Non proliferative diabetic retinopathy - Page 1 : comparemela.com

EyePoint Pharmaceuticals, Inc : EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals, Inc : EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Macau generalUnited statesHong kongAmy phillipsExperte carsten storkJay dukerZwei rohstoff chancenChristina tartagliaEyepoint pharmaceuticalsDrug administrationExchange commissionGreen room communicationsEyepoint pharmaceuticals incEyepoint pharmaceuticals nasdaqBetta pharmaceuticalsEquinox sciences

Ocuphire Pharma To Present In The BIO CEO & Investor Conference

Ocuphire Pharma To Present In The BIO CEO & Investor Conference
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkOcuphire pharmaCorey davisGeorge magrathMarriott marquisCompany presentationOcuphire pharma incViatris incSpecial protocol assessmentNon proliferative diabetic retinopathyProliferative diabetic retinopathy

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A Hold At This Time (EYPT)

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A Hold At This Time (EYPT)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesZorica nastasicIcon bioscience incEyepoint pharmaceuticalsEyepoint pharmaceuticals incSivida corpPoint pharmaceuticalsIcon bioscienceEyepoint investor presentation januaryAge related macular degenerationNon proliferative diabetic retinopathyDiabetic macular edemaGeographic atrophySeeking alpha

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesOcuphire pharmaGeorge magrathCorey davisNirav jhaveriAshwath jayagopalOcuphire pharma incViatris incChief scientificDevelopment officerChief financial officerNasdaq listing ruleSpecial protocol assessmentNon proliferative diabetic retinopathyProliferative diabetic retinopathySci advisors

Ocuphire Pharma Reports Inducement Grants Under Nasdaq

FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company.

United statesNirav jhaveriCorey davisAshwath jayagopalGeorge magrathOcuphire pharmaViatris incOcuphire pharma incChief scientificDevelopment officerChief financial officerNasdaq listing ruleSpecial protocol assessmentNon proliferative diabetic retinopathyProliferative diabetic retinopathySci advisors